share_log

Piper Sandler Reiterates Overweight on Legend Biotech, Maintains $90 Price Target

Benzinga ·  Jun 18 01:11

Piper Sandler analyst Edward Tenthoff reiterates Legend Biotech (NASDAQ:LEGN) with a Overweight and maintains $90 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment